The stock of Sunshine Biopharma Inc (SBFM) has gone down by -11.58% for the week, with a -90.87% drop in the past month and a -96.53% drop in the past quarter. The volatility ratio for the week is 14.60%, and the volatility levels for the past 30 days are 24.57% for SBFM. The simple moving average for the last 20 days is -80.58% for SBFM stock, with a simple moving average of -96.69% for the last 200 days.
Is It Worth Investing in Sunshine Biopharma Inc (NASDAQ: SBFM) Right Now?
The 36-month beta value for SBFM is at -1.00. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SBFM is 0.95M, and currently, shorts hold a 7.35% of that float. The average trading volume for SBFM on May 06, 2024 was 1.97M shares.
SBFM) stock’s latest price update
Sunshine Biopharma Inc (NASDAQ: SBFM) has seen a rise in its stock price by 0.30 in relation to its previous close of 0.84. However, the company has experienced a -11.58% decline in its stock price over the last five trading sessions. InvestorPlace reported 2024-03-04 that Sunshine Biopharma (NASDAQ: SBFM ) stock is falling on Monday after the pharmaceutical company received a delisting notice from the Nasdaq Exchange. That delisting notice notes that shares of SBFM stock have been trading for less than the $1 minimum bid price for too long.
SBFM Trading at -84.71% from the 50-Day Moving Average
After a stumble in the market that brought SBFM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.40% of loss for the given period.
Volatility was left at 24.57%, however, over the last 30 days, the volatility rate increased by 14.60%, as shares sank -91.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -86.02% lower at present.
During the last 5 trading sessions, SBFM fell by -11.58%, which changed the moving average for the period of 200-days by -98.28% in comparison to the 20-day moving average, which settled at $3.8582. In addition, Sunshine Biopharma Inc saw -96.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SBFM starting from Slilaty Steve N., who purchase 100,000 shares at the price of $0.10 back on Mar 04 ’24. After this action, Slilaty Steve N. now owns 130,000 shares of Sunshine Biopharma Inc, valued at $10,000 using the latest closing price.
Slilaty Steve N., the Chief Executive Officer of Sunshine Biopharma Inc, purchase 20,000 shares at $0.10 during a trade that took place back on Feb 08 ’24, which means that Slilaty Steve N. is holding 30,000 shares at $2,000 based on the most recent closing price.
Stock Fundamentals for SBFM
Current profitability levels for the company are sitting at:
- -0.19 for the present operating margin
- 0.34 for the gross margin
The net margin for Sunshine Biopharma Inc stands at -0.19. The total capital return value is set at -0.21. Equity return is now at value -21.04, with -15.84 for asset returns.
Based on Sunshine Biopharma Inc (SBFM), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -13.34. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -32.74.
Currently, EBITDA for the company is -4.64 million with net debt to EBITDA at 4.2. When we switch over and look at the enterprise to sales, we see a ratio of -0.61. The receivables turnover for the company is 9.44for trailing twelve months and the total asset turnover is 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.48.
Conclusion
In conclusion, Sunshine Biopharma Inc (SBFM) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
